SCHEMBL7847006

SCHEMBL7847006

CCOC(=O)COC(=O)c1cn(C2CC2)c2c(F)c(N3CC4CCOC4(CNC(=O)OC(C)(C)C)C3)c(F)cc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.44
KCNH2 Q12809 6/20 0.39
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.35
POLB P06746 2/20 0.35
OPRM1 P35372 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
OPRD1 P41143 1/20 0.35
KMT2A Q03164 1/20 0.34
TOP2A P11388 2/20 0.34
TOP2B Q02880 2/20 0.34
PRKD3 O94806 1/20 0.34
ALOX15 P16050 1/20 0.34
CLK2 P49760 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7847474 0.95 ADRB2 (0.48) ADRB2KCNH2KDM4EHPGDCYP2C19
SCHEMBL7846534 0.92 ADRB2 (0.42) ADRB2KCNH2KDM4EHPGDALDH1A1
SCHEMBL7835489 0.90 ADRB2 (0.43) ADRB2KCNH2KDM4EHPGDCYP2C19
SCHEMBL7846924 0.90 KCNH2 (0.46) KCNH2KDM4EHPGDALDH1A1POLB
SCHEMBL7846922 0.90 KCNH2 (0.46) KCNH2KDM4EHPGDALDH1A1POLB
SCHEMBL7836509 0.90 KCNH2 (0.46) KCNH2KDM4EHPGDALDH1A1POLB
SCHEMBL7836504 0.90 KCNH2 (0.46) KCNH2KDM4EHPGDALDH1A1POLB
SCHEMBL7494366 0.90 KCNH2 (0.46) KCNH2KDM4EHPGDALDH1A1POLB
SCHEMBL7835231 0.90 ADRB2 (0.40) ADRB2KCNH2KDM4EHPGDCYP2C19
SCHEMBL7848101 0.89 ADRB2 (0.40) ADRB2KCNH2KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010036941-A1 Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders PETERSEN UWE (DE) 2001-11-01 US disclosed
US-6288081-B1 Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith BAYER AKTIENGESELLSCHAFT (DE) 2001-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036941-A1 Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders OXER1, AOC3, PAM ADRB2 2223/4885KCNH2 3936/4885KDM4E 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.